WebSep 10, 2024 · We are using the FSHD-CTRN patient engagement model to address specific aims or difficulties encountered in running the proposed study; for example, defining what would be clinically meaningful to people with FSHD, addressing concerns related to participating in clinical studies, and issues with recruitment and retention. WebCambridge, Mass., May 21, 2024 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, and the FSHD Clinical Trial Research Network (CTRN) today announced the initiation of a clinical trial readiness study.
FSHD Society Expands the FSHD Clinical Trial Research Network
WebMay 3, 2024 · Objective: 1. Determine the association between percent lean muscle mass in the upper/lower extremities and corresponding clinical outcome assessments. 2. Determine the longitudinal change in whole body and regional lean muscle mass over 1 year. Background: Facioscapulohumeral muscular dystrophy (FSHD) is a slowly progressive … WebMar 9, 2024 · By using a standard evidence-based approach, based on the Dutch FSHD guideline, the goal is to help neurologists and other physicians to understand how to confirm the diagnosis of FSHD and guide standardised patient care and treatment plans, which are needed since there are many trials expected to roll out in the upcoming years. how to remove gildan tags
FSHD Clinical Trial Research Network
WebApr 8, 2024 · 268th ENCM workshop - Genetic diagnosis, clinical classification, outcome measures, and biomarkers in Facioscapulohumeral Muscular Dystrophy (FSHD): relevance for clinical trials 1 Author links open overlay panel Federica Montagnese a , Katy de Valle b , Richard J.L.F. Lemmers c , Karlien Mul d , Julie Dumonceaux e , WebThe activities funded include blood-based biomarker discovery & validation and the addition of 50 more subjects with FSHD to the MOVE/MOVE+ Natural History studies. The CTRN … WebApr 21, 2024 · The FSHD Society is launching a collaboration involving the FSHD Clinical Trial Research Network (CTRN) and BullFrog AI, an innovator in artificial intelligence, to analyze the largest-yet natural history dataset collected from patients with facioscapulohumeral muscular dystrophy (FSHD). how to remove gifs from android